Genix Pharmaceuticals Corporation

GENX

CA37232A1093

Food Processing

Delayed Toronto S.E. Other stock markets 11:14:16 09/05/2024 pm IST			5-day change	1st Jan Change
0.05 ^CAD	+11.11%		+42.86%	+150.00%

26/03	Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
28/02	Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023	CI

Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2020

September 29, 2020 at 04:31 am IST

Genix Pharmaceuticals Corporation announced earnings results for the third quarter ended July 31, 2020. For the third quarter, the company announced net loss was CAD 71,271 compared to CAD 38,832 a year ago. For the nine months, sales was CAD 0 compared to CAD 135,003 a year ago. Net loss was CAD 155,595 compared to CAD 138,041 a year ago.

Latest news about Genix Pharmaceuticals Corporation

Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2024	27/03	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2023	28/02	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	27/23/27	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	27/23/27	CI
Genix Pharmaceuticals Corporation Announces Board Changes	27/23/27	CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2022	28/23/28	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	15/22/15	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	29/22/29	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the First Quarter Ended January 31, 2022	26/22/26	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2021	01/22/01	CI
Genix Pharmaceuticals Corporation Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2021	22/21/22	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter Ended April 30, 2021	25/21/25	CI
Genix Pharmaceuticals : Starts Trading on OTCQB Venture Market Exchange	21/21/21	MT
Genix Pharmaceuticals Corporation Appoints Mahmoud Aziz to the Board and as President	20/21/20	CI
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for First Generic Thyroid Medication	02/21/02	CI
Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions for its First Ten Ophthalmic Drugs with Health Canada	22/21/22	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Full Year Ended October 31, 2020	01/21/01	CI
Genix Pharmaceuticals Corporation Announces Executive Changes	15/20/15	CI
Genix Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter Ended July 31, 2020	29/20/29	CI
Genix Pharmaceuticals Corporation completed the acquisition of global distribution, sales and marketing rights and interest for Flu-X(r) from Canagen Pharmaceuticals Inc.	28/20/28	CI
Genix Pharmaceuticals Corporation Elects Darryl Yea to the Board of Directors	22/20/22	CI
Genix Pharmaceuticals Corporation Welcomes Monita Faris as Secretary	06/20/06	CI
Genix Pharmaceuticals Corporation announced that it has received CAD 1.026734 million in funding	06/20/06	CI

Chart Genix Pharmaceuticals Corporation

Duration

Period

More charts

Company Profile

Genix Pharmaceuticals Corporation is a nutraceutical and generic ophthalmic drugs company. The Company is focused on the research, development, manufacturing, licensing, and sales of healthcare products. Its products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single-molecule generic drugs. The Company is engaged in marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Bimatoprost 0.01% Eye Drops, Timolol 0.5% Eye Drops, Loteprednol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Brimonidine 0.2% Eye Drops. The Company sells its ophthalmic products through traditional pharmacy and drugstore retail outlets and as well as direct to consumers and e-commerce platforms.

Sector

Food Processing

Calendar

26/09/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Special Foods & Wellbeing Products

	1st Jan change	Capi.
GENIX PHARMACEUTICALS CORPORATION	+150.00%	2.17M
ZHEJIANG NHU COMPANY LTD.	+19.40%	8.71B
BELLRING BRANDS, INC.	+8.05%	7.81B
CSPC INNOVATION PHARMACEUTICAL CO., LTD.	+7.42%	6.69B
THE SIMPLY GOOD FOODS COMPANY	-5.63%	3.78B
BYHEALTH CO., LTD	-6.64%	3.77B
XIAMEN KINGDOMWAY GROUP COMPANY	-3.06%	1.41B
HERBALIFE LTD.	-26.51%	1.13B
SIRIO PHARMA CO., LTD.	+20.86%	1.07B
USANA HEALTH SCIENCES, INC.	-11.36%	906M

Special Foods & Wellbeing Products